Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
ct largest » _ largest (Expand Search)
b large » _ large (Expand Search), _ larger (Expand Search)
a large » _ large (Expand Search)
Showing 41 - 60 results of 2,216 for search '(((( b large decrease ) OR ( a large decrease ))) OR ( ct largest decrease ))', query time: 0.56s Refine Results
  1. 41
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 <sup>a</sup> indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  2. 42
    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.4), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  3. 43
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  4. 44
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  5. 45
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  6. 46
    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.8), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  7. 47
    Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c) Urban/Rural Class.

    Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for access question between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c... by David Henderson (4612354)

    Published 2025
    Save to List
    Saved in:
  8. 48
    Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues and c) Urban/Rural Class.

    Relative Index of Inequality (RII) and 95% Confidence Interval (CI) for overall satisfaction between most a least deprived SIMD decile by A) Age and sex B) Number of Health Issues... by David Henderson (4612354)

    Published 2025
    Save to List
    Saved in:
  9. 49
    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Save to List
    Saved in:
  10. 50
    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Save to List
    Saved in:
  11. 51
    (a) A cropped microscope image from the LIVECell test set, (b) overlayed ground-truth cell masks, and (c) a distance map computed from these cell masks.

    (a) A cropped microscope image from the LIVECell test set, (b) overlayed ground-truth cell masks, and (c) a distance map computed from these cell masks. by Alexandra Dunnum VandeLoo (22209218)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 52
    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage.

    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

    Published 2025
    Save to List
    Saved in:
  13. 53
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 54
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 55
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 56
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 57
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 58
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 59
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 60
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: